Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lacticaseibacillus paracasei ET-22
- Development stage
- Unknown
- Lead developer
- Bioflag Biotech
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
lacticaseibacillus paracasei ET-22 (formerly known as Lactobacillus paracasei ET-22) is a probiotic strain developed by Bioflag Biotech, a subsidiary of Ausnutria Dairy. It is utilized in both live (ET-22.L) and heat-killed (ET-22.HK, postbiotic) forms. The strain is primarily developed for oral health applications, specifically targeting halitosis (bad breath) and dental caries (cavities) by inhibiting the growth of oral pathogens like Streptococcus mutans and Fusobacterium nucleatum, and reducing the formation of cariogenic biofilms. Additionally, it is investigated for gut health benefits, including the regulation of intestinal microbiota and the alleviation of constipation.
- Other names
- L. paracasei ET-22Lactobacillus paracasei ET-22
02
Targets
F. nucleatum (Fusobacterium nucleatum)Gtf (Streptococcus mutans glucosyltransferase)
Beyond the preview
Go deeper on lacticaseibacillus paracasei ET-22.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lacticaseibacillus paracasei ET-22.